-
Je něco špatně v tomto záznamu ?
Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations
M. Gregová, J. Hojný, K. Němejcová, M. Bártů, M. Mára, B. Boudová, J. Laco, L. Krbal, I. Tichá, P. Dundr
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
RVO 64165
Ministerstvo Zdravotnictví Ceské Republiky (CZ)
Progres Q28/LF1
Univerzita Karlova v Praze
UNCE 204065
Univerzita Karlova v Praze
SVV 260367
Univerzita Karlova v Praze
EF16_013/0001674
European Regional Development Fund
BBMRI_CZ LM2015089
European Regional Development Fund
CZ.2.16/3.1.00/24509
European Regional Development Fund
NLK
Medline Complete (EBSCOhost)
od 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1995
- MeSH
- buněčné jádro patologie MeSH
- dospělí MeSH
- fumarasa genetika MeSH
- leiomyom genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádorové biomarkery genetika MeSH
- nádory dělohy genetika patologie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Leiomyoma with bizarre nuclei (LBN) is an uncommon variant of uterine smooth muscle neoplasm. Involvement of fumarate hydratase (FH) has been suggested in the pathogenesis of a subset of LBN. The goal of our study is to assess the clinicopathological, morphological, immunohistochemical and molecular findings focusing on FH in LBNs (n = 108) and compare it with the findings in usual leiomyomas (UL; n = 50) and leiomyosarcomas (LMS; n = 42). Immunohistochemically, loss of FH expression was found in 67/108 of LBN, 1/50 of UL and in no LMS. Class 4/5 FH mutations were detected in 15/53 LBN with sufficient DNA quality for molecular analysis. Pathogenic variants of the FH gene were detected in neither UL nor LMS. Local recurrence after surgery was present in 18/92 of LBN patients, 7 of which were histologically verified and 2 of which were found to be LBN. Our results confirmed that LBN behave in a benign fashion, although they may relapse. FH gene mutations were a common finding only in LBN, but not in UL and LMS. Immunohistochemistry with an antibody against FH seems to have a good sensitivity (87%) and moderate specificity (58%) with regard to predicting FH gene mutations and could be used as a screening method in tumors with features suggestive of FH alterations to identify patients who are at risk for the FH aberrations.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020415
- 003
- CZ-PrNML
- 005
- 20210830102118.0
- 007
- ta
- 008
- 210728s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12253-019-00739-5 $2 doi
- 035 __
- $a (PubMed)31471882
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Gregová, Mária $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 245 10
- $a Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations / $c M. Gregová, J. Hojný, K. Němejcová, M. Bártů, M. Mára, B. Boudová, J. Laco, L. Krbal, I. Tichá, P. Dundr
- 520 9_
- $a Leiomyoma with bizarre nuclei (LBN) is an uncommon variant of uterine smooth muscle neoplasm. Involvement of fumarate hydratase (FH) has been suggested in the pathogenesis of a subset of LBN. The goal of our study is to assess the clinicopathological, morphological, immunohistochemical and molecular findings focusing on FH in LBNs (n = 108) and compare it with the findings in usual leiomyomas (UL; n = 50) and leiomyosarcomas (LMS; n = 42). Immunohistochemically, loss of FH expression was found in 67/108 of LBN, 1/50 of UL and in no LMS. Class 4/5 FH mutations were detected in 15/53 LBN with sufficient DNA quality for molecular analysis. Pathogenic variants of the FH gene were detected in neither UL nor LMS. Local recurrence after surgery was present in 18/92 of LBN patients, 7 of which were histologically verified and 2 of which were found to be LBN. Our results confirmed that LBN behave in a benign fashion, although they may relapse. FH gene mutations were a common finding only in LBN, but not in UL and LMS. Immunohistochemistry with an antibody against FH seems to have a good sensitivity (87%) and moderate specificity (58%) with regard to predicting FH gene mutations and could be used as a screening method in tumors with features suggestive of FH alterations to identify patients who are at risk for the FH aberrations.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a buněčné jádro $x patologie $7 D002467
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fumarasa $x genetika $7 D005649
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leiomyom $x genetika $x patologie $7 D007889
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a nádory dělohy $x genetika $x patologie $7 D014594
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Mára, Michal $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Boudová, Barbora $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Laco, Jan $u The Fingerland Department of Pathology, Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové, Charles University, Prague, Czech Republic
- 700 1_
- $a Krbal, Lukáš $u The Fingerland Department of Pathology, Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové, Charles University, Prague, Czech Republic
- 700 1_
- $a Tichá, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. ivana.ticha@vfn.cz
- 700 1_
- $a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz
- 773 0_
- $w MED00180530 $t Pathology oncology research : POR $x 1532-2807 $g Roč. 26, č. 3 (2020), s. 1527-1537
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31471882 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102119 $b ABA008
- 999 __
- $a ok $b bmc $g 1691065 $s 1140861
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 26 $c 3 $d 1527-1537 $e 20190831 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
- GRA __
- $a RVO 64165 $p Ministerstvo Zdravotnictví Ceské Republiky (CZ)
- GRA __
- $a Progres Q28/LF1 $p Univerzita Karlova v Praze
- GRA __
- $a UNCE 204065 $p Univerzita Karlova v Praze
- GRA __
- $a SVV 260367 $p Univerzita Karlova v Praze
- GRA __
- $a EF16_013/0001674 $p European Regional Development Fund
- GRA __
- $a BBMRI_CZ LM2015089 $p European Regional Development Fund
- GRA __
- $a CZ.2.16/3.1.00/24509 $p European Regional Development Fund
- LZP __
- $a Pubmed-20210728